CLDI (Calidi Biotherapeutics) General and Admin. Expense: $9.47 Mil (TTM As of Mar. 2026)


CLDI Calidi Biotherapeutics Inc CLDI
12 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics General and Admin. Expense?

Calidi Biotherapeutics CLDI +0.64% 12 General and Admin. Expense is $9.47 Mil as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Calidi Biotherapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $1.60 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $9.47 Mil.

Calidi Biotherapeutics General and Admin. Expense Related Terms

Calidi Biotherapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics General and Admin. Expense Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 6.16 15.90 15.98 12.90 10.50

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.64 3.07 2.69 2.11 1.60
CLDI
12GF Score
Calidi Biotherapeutics Inc CLDI
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Calidi Biotherapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $9.47 Mil mean?
Calidi Biotherapeutics (CLDI) has a General and Admin. Expense of $9.47 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' General and Admin. Expense too high?
Calidi Biotherapeutics' current General and Admin. Expense is $9.47 Mil. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' General and Admin. Expense compare to CMND and BIXT?
Calidi Biotherapeutics' General and Admin. Expense of $9.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current General and Admin. Expense is $9.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current General and Admin. Expense of $9.47 Mil. The current General and Admin. Expense is $9.47 Mil. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current General and Admin. Expense is $9.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score

Get the complete analysis for CLDI

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price